KNSA Stock: Price, Earnings History and SEC Filings
Kiniksa Pharmaceuticals International, plc (KNSA) last traded at $92.24, down 5.45% on the latest session and up 23.6% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $0.56 against an analyst estimate of $0.32, a beat of 75.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
KNSA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 27, 2026 | $0.56 | $0.32 | +75.00% |
| Jun 2026 | Jul 28, 2026 | $0.30 | $0.30 | +0.00% |
| Mar 2026 | Apr 28, 2026 | $0.27 | $0.18 | +50.00% |
| Dec 2025 | Feb 24, 2026 | $0.17 | $0.29 | -41.38% |
KNSA beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How KNSA reacts to earnings
Across its last 8 earnings releases, KNSA moved 15.1% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-27 | Before open | +22.23% |
| 2026-07-28 | Before open | +25.03% |
| 2026-04-28 | Before open | +23.48% |
| 2026-02-24 | Before open | -8.21% |
| 2026-01-12 | After close | -6.13% |
| 2025-10-28 | Before open | -2.88% |
| 2025-07-29 | Before open | +12.32% |
| 2025-04-29 | Before open | +20.54% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
KNSA financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $678M | $59M | $136M | 8.7% | $0.75 |
| 2024 | $423M | -$43M | $25M | -10.2% | $-0.60 |
| 2023 | $270M | $14M | $13M | 5.2% | $0.20 |
| 2022 | $220M | $183M | $6M | 83.3% | $2.60 |
| 2021 | $39M | -$158M | -$127M | -409.7% | $-2.30 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for KNSA
- 10-Q · Oct 27, 2026
- 8-K · Oct 27, 2026Results of operations, Financial statements and exhibits
- 8-K · Oct 22, 2026Officer or director change
- 10-Q · Jul 28, 2026
- 8-K · Jul 28, 2026Results of operations, Financial statements and exhibits
- 8-K · May 29, 2026Shareholder vote
- 8-K · May 26, 2026Material agreement, Financial statements and exhibits
- 8-K · May 1, 2026Officer or director change
- 10-Q · Apr 28, 2026
- 8-K · Apr 28, 2026Results of operations, Financial statements and exhibits
Insider filing activity
KNSA insiders filed 8 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
KNSA news
- Stock Market: Google, Amazon, Intel, ServiceNow Trigger Tech Wreck, But Other Sectors Solid: Weekly ReviewOct 30, 2026 · finance.yahoo.com
- Kiniksa (KNSA) Stock Jumps As Q3 Results Fuel Growth DebateOct 28, 2026 · finance.yahoo.com
- Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term InvestorsOct 27, 2026 · fool.com
- Kiniksa Pharmaceuticals, Ltd. Q3 2026 Earnings Call SummaryOct 27, 2026 · app.moby.co
- Kiniksa (KNSA) Q3 2026 Earnings Call TranscriptOct 27, 2026 · fool.com
- What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings CallOct 27, 2026 · marketbeat.com
- Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass EstimatesOct 27, 2026 · finance.yahoo.com
- Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio ExecutionOct 27, 2026 · finance.yahoo.com
About Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc (KNSA) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. Its fiscal year ends in December.